Please provide your email address to receive an email when new articles are posted on . “Fifteen percent of [patients with B-cell ALL] are primary refractory or relapse after initial treatment, but ...
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study Fifty patients were treated (20 patients had ...
Adaptimmune ($ADAP) has responded to the failure of its T-cell therapy to induce objective clinical responses in ovarian cancer patients by adding fludarabine--the ...
Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Treosulfan plus fludarabine conditioning after allogeneic hematopoietic stem cell ...
CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’Adulte Fludarabine and cyclophosphamide produced ...
Fludarabine, an immunosuppressive and cytotoxic purine analog, is a common constituent of conditioning for hematopoietic cell transplantation (HCT). Fludarabine (F-ara-AMP) is a prodrug that is ...
GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...
To earn CME related to this news article, click here. January 9, 2009 — The US Food and Drug Administration (FDA) has approved fludarabine phosphate tablets for the treatment of B-cell chronic ...
Kite, analysts unfazed by Juno trial issues, say low-dose fludarabine safe By Ben Adams Jul 14, 2016 6:54am blood cancer Juno Therapeutics Kite Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results